175 related articles for article (PubMed ID: 23810012)
1. The functional role of Notch signaling in triple-negative breast cancer.
Speiser JJ; Erşahin C; Osipo C
Vitam Horm; 2013; 93():277-306. PubMed ID: 23810012
[TBL] [Abstract][Full Text] [Related]
2. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
3. NOTCH4 is a potential therapeutic target for triple-negative breast cancer.
Nagamatsu I; Onishi H; Matsushita S; Kubo M; Kai M; Imaizumi A; Nakano K; Hattori M; Oda Y; Tanaka M; Katano M
Anticancer Res; 2014 Jan; 34(1):69-80. PubMed ID: 24403446
[TBL] [Abstract][Full Text] [Related]
4. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
5. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer.
Speiser J; Foreman K; Drinka E; Godellas C; Perez C; Salhadar A; Erşahin Ç; Rajan P
Int J Surg Pathol; 2012 Apr; 20(2):139-45. PubMed ID: 22084425
[TBL] [Abstract][Full Text] [Related]
6. The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.
Pamarthy S; Jaiswal MK; Kulshreshtha A; Katara GK; Gilman-Sachs A; Beaman KD
Oncotarget; 2015 Oct; 6(33):34206-20. PubMed ID: 26418877
[TBL] [Abstract][Full Text] [Related]
7. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
8. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
9. Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
Rangel MC; Bertolette D; Castro NP; Klauzinska M; Cuttitta F; Salomon DS
Breast Cancer Res Treat; 2016 Apr; 156(2):211-26. PubMed ID: 26968398
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targets of triple-negative breast cancer: a review.
Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
[TBL] [Abstract][Full Text] [Related]
11. Notch in mammary gland development and breast cancer.
Politi K; Feirt N; Kitajewski J
Semin Cancer Biol; 2004 Oct; 14(5):341-7. PubMed ID: 15288259
[TBL] [Abstract][Full Text] [Related]
12. Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures.
Locatelli M; Curigliano G
Curr Opin Oncol; 2017 Nov; 29(6):411-427. PubMed ID: 28914645
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
Dong Y; Li A; Wang J; Weber JD; Michel LS
Cancer Res; 2010 Jul; 70(13):5465-74. PubMed ID: 20570903
[TBL] [Abstract][Full Text] [Related]
15. Shotgun proteomics of archival triple-negative breast cancer samples.
Gámez-Pozo A; Ferrer NI; Ciruelos E; López-Vacas R; Martínez FG; Espinosa E; Vara JÁ
Proteomics Clin Appl; 2013 Apr; 7(3-4):283-91. PubMed ID: 23436753
[TBL] [Abstract][Full Text] [Related]
16. Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype.
Giuli MV; Giuliani E; Screpanti I; Bellavia D; Checquolo S
J Oncol; 2019; 2019():8707053. PubMed ID: 31379945
[TBL] [Abstract][Full Text] [Related]
17. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: investigating potential molecular therapeutic target.
Papa A; Caruso D; Tomao S; Rossi L; Zaccarelli E; Tomao F
Expert Opin Ther Targets; 2015 Jan; 19(1):55-75. PubMed ID: 25307277
[TBL] [Abstract][Full Text] [Related]
20. Cadherins and the mammary gland.
Knudsen KA; Wheelock MJ
J Cell Biochem; 2005 Jun; 95(3):488-96. PubMed ID: 15838893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]